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Background: Parkinson’s disease is a genetically complex disease with mixed mode of inheritance.
Recently, a haplotype across the sepiapterin reductase (SPR) gene, which is located in the PARK3 linkage
region, was shown to modulate age of onset of Parkinson’s disease in sibships from North America.
Objective: To make a thorough assessment of the SPR gene region in sporadic Parkinson’s disease.
Methods: A linkage study in 122 European sibship families with five microsatellite and 17 single
nucleotide polymorphism (SNP) markers in and around the SPR gene region, and an association analysis
in 340 sporadic cases of Parkinson’s disease and 680 control subjects from Germany with 40 SNPs.
Linkage was evaluated by non-parametric linkage scores and genotypic or haplotype association was
tested by regression analysis, assuming different risk effect models.
Results: Significant LOD scores between 2 and 3 were obtained at the two SPR-flanking markers D2S2110
and D2S1394 and seven SNP markers around the SPR gene. We found the previously reported promoter
SNP rs1876487 also significantly associated with age of onset in our sib pair families (p-value 0.02). One
strong linkage disequilibrium (LD) block of 45 kb including the entire SPR gene was observed. Within this
LD block all 14 inter-correlated SNPs were significantly associated with Parkinson’s disease affection status
(p-value 0.004).
Conclusions: DNA polymorphisms in a highly intercorrelated LD block, which includes the SPR gene,
appear to be associated with both sporadic and familial Parkinson’s disease. This confirms a previous
study showing that SPR potentially modulates the onset of or risk for Parkinson’s disease.
P
arkinson’s disease is one of the most common neurode-
generative disorders, affecting around 2% of the popula-
tion above 65 years of age.1 Pathological features include
degeneration of dopaminergic neurones of the substantia
nigra pars compacta, and the presence of eosinophilic
inclusions known as Lewy bodies in affected brain areas.2
Six genes for monogenically inherited forms of Parkinson’s
disease, which account for only a small fraction of all
Parkinson’s disease cases, have been identified. It has been
shown that mutations in the parkin gene (PARK2), in the
PINK1 gene (PARK6), and in the DJ-1 gene (PARK7) cause
autosomal recessive early onset parkinsonism.3–5 The a-
synuclein gene (SNCA) has been implicated in rare forms of
dominantly inherited Parkinson’s disease (PARK1), either by
missense mutations or gene multiplications.6–8 Leucine-rich
repeat kinase 2 (LRRK2) has been identified as the disease
causing gene for late onset autosomal dominant parkinson-
ism (PARK8).9 10 In addition, various genetic studies have
detected linkage to several other chromosomal regions, for
which the disease causing genes have yet to be detected:
PARK3 (2p13), PARK9 (1p36), PARK10 (1p32), and
PARK11(2q13).11 Eight genome scans evaluating linkage with
affection status as well as with age of onset have been carried
out using sibling pair cohorts as well as multiplex families
from North American and European populations.12–18
We have mapped a locus for autosomal dominant
Parkinson’s disease on chromosome 2p13 (PARK3)19 which
we further refined to 2.5 megabases.20 Three other genome
scans confirmed the PARK3 locus.14 16 17 In a refinement of
the locus position, DeStefano et al found evidence for
association between later Parkinson’s disease age at onset
and allele 174 of marker D2S1394, which is close to the SPR
gene.18 Karamohamed et al extended the work by genotyping
single nucleotide polymorphisms (SNPs) in the vicinity of
marker D2S1394.21 They reported association of one SNP and
a haplotype across the SPR gene with age of onset in sibships
of North American origin.
Here, we thoroughly assess the SPR gene region in sporadic
Parkinson’s disease cases ascertained from Germany, and in
familial Parkinson’s disease samples from five different
European countries. After characterising the linkage disequi-
librium (LD) structure in the SPR gene region, we further
refined association signals for Parkinson’s disease suscept-
ibility to haplotypes and SNPs within an LD block comprising
the SPR gene.
METHODS
We conducted our study in two parts. First, we genotyped
five short tandem repeat (STR) markers and 17 SNPs from
the PARK3 core region centred around the SPR gene (table 1,
Abbreviations: LD, linkage disequilibrium; MAF, minor allele
frequency; NPL, non-parametric linkage scores; SNP, single nucleotide
polymorphism; SPR, sepiapterin reductase; STR, short tandem repeat
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fig 1) in a cohort of European affected siblings (122 sibships).
In the second part of our study, an additional 23 SNPs,
chosen to cover the SPR gene and flanking regions (fig 1),
were genotyped in 340 German sporadic Parkinson’s disease
patients and 680 controls.
Recruitment of Parkinson’s disease families
In all, 122 families from five European countries were
ascertained through the European Consortium on Genetic
Susceptibility in Parkinson’s disease (GSPD). We included
families having at least two affected siblings. A total of 35
families from Germany, 26 from the UK, 12 from the
Netherlands, 33 from France, and 16 from Italy were
ascertained. Characteristics of the families are given in table 2.
After appropriate informed consent was obtained, blood
samples were drawn from the individuals for DNA extraction.
Families suggestive for dominant inheritance were screened
for known LRRK2 mutations. In families suggestive for
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Figure 1 Linkage disequilibrium (LD) structure around the sepiapterin reductase (SPR) gene region. All marker positions and genes are indicated on
the physical map. Black cells = high pairwise r2 values; grey cells = intermediate pairwise r2 values; white cells = low pairwise r2 values. Additional SNPs
genotyped are indicated by arrows. Exons are indicated by vertical bars.
Table 1 Non-parametric logarithm of odds (LOD) scores of single nucleotide
polymorphisms with affection status (sibship data)
SNP Germany UK France Italy Netherlands All
rs1876488 0.51 0.25 0.61 0.23 0.45 2.91*
rs1396107 0.37 0.27 20.25 20.17 0.53 0.35
rs1508060 0.42 0.00 1.89 0.00 0.00 2.18*
rs1567230 20.27 0.25 20.07 20.10 0.34 0.22
rs2135985 20.01 0.73 0.76 20.71 0.41 0.98
rs1876491 20.02 20.13 20.06 20.16 0.59 20.14
rs2421095 20.13 0.48 0.60 20.08 0.45 2.70*
rs1876487 0.36 0.30 20.06 20.15 0.43 0.40
rs1150500 20.01 20.01 20.85 20.41 0.11 1.41
rs1561244 0.00 0.02 20.17 20.27 0.05 20.16
rs1561245 20.11 0.39 0.60 0.23 0.45 1.56
rs4852903 0.02 0.49 0.60 0.23 0.45 2.19*
rs989040 1.62 0.48 0.61 0.23 0.45 2.63*
rs1561247 0.12 1.38 0.00 0.00 0.00 2.26*
rs999494 20.33 0.60 0.64 20.41 0.72 0.78
rs1465805 1.58 0.00 0.00 0.00 0.00 2.48*
rs3980960 1.49 0.83 0.53 20.51 0.33 0.74
*p value ,0.05.
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recessive inheritance with early onset (,45 years) in at least
one affected member, the parkin, PINK1 and DJ-1 genes
were completely sequenced and mutations were excluded.
Recruitment of sporadic Parkinson’s disease patients
Parkinson’s disease patients were recruited mainly from the
departments of neurology at the Universities of Munich and
Tu¨bingen. Specialists in movement disorders examined the
patients. Diagnosis was established according to UK Brain
Bank criteria.22 The median age at onset was 55.4 years
(range¡19.1). As controls we used 680 healthy, age and sex
matched subjects from the KORA (Cooperative Research in
the Region of Augsburg) Survey 2000, which involved a large,
population based sample.
Genotyping of STRs
We genotyped the five STR markers D2S2110, D2S1394,
D2S2111, D2S145, and D2S2109 with an average spacing of
0.2 cM from the PARK3 core region, as defined by West et al.20
The new marker order was obtained from the Marshfield
Genetic Laboratories Map. Mendelian inconsistencies in the
genotypic data were checked by using the program
PedCheck.23
Genotyping of SNPs
Within the PARK3 core region we focused on the SPR gene
region (4 kb SPR gene plus 94 kb flanking regions; in all
98 kb; see fig 1). Forty SNPs with an average spacing of
2.5 kb were identified using public databases. All SNPs
showed high genotyping quality and Hardy–Weinberg
equilibrium in the control subjects. Genotyping was under-
taken using the matrix assisted laser desorption/ionisation
time of flight (MALDI-TOF) mass spectrometry method
(Sequenom, San Diego, California, USA).
Statistical analysis
We used the non-parametric linkage scores (NPL) for the
analysis of the sibship data.24 NPL compares the estimated
proportion of alleles shared by identical by descent siblings
with the null hypothesis of no linkage. The Sall function in
Genehunter was used for calculation. The age of onset effect
in siblings was tested by the quantitative transmission
disequilibrium test (QTDT) using an orthogonal and monks
model.25 This allows one to incorporate pedigrees without
parental genotypes. Whenever there are more than two
siblings in the families, allelic transmission scores were used
to assess the association.
The method of Gabriel et al, as implemented in Haploview,
was used to construct LD blocks from SNPs with minor allele
frequencies (MAF) of more than 0.05.26 In the sporadic
patients, logistic regression was used to test for association
between SNP alleles or haplotypes and Parkinson’s disease
affection status as implemented in UNPHASED.27 A stepwise
approach was employed to determine which variants
independently influence the risk of the disease. This
approach allows the effect at a locus to be assessed for
conditioning on alleles at other loci. A linear regression
model was used to assess the age of onset effect.
RESULTS
Analysis of sibship families
We obtained overall non-parametric LOD scores with affec-
tion status of 2.12 and 1.96 at the SPR-neighbouring markers
D2S2110 and D2S1394, respectively. After the exclusion of six
families with PARK8 mutations the LOD scores increased to
2.76 and 2.08 at these two markers, as shown in table 3.
Family sets from single countries showed the same trend
but were underpowered to obtain significant LOD scores
except for the UK sample. Seven of the 17 SNPs located
between the STR markers D2S2110 and D2S1394 also
showed significant LOD scores (table 1).
We further analysed the age of onset effect in our sibship
samples. The STR marker D2S2110 (p = 0.04) and the SNP
marker rs1876487 (p = 0.04) showed significant association
with age of onset. D2S2110 is the only genotyped STR marker
which is located within the SPR LD block described below.
The SPR promoter SNP rs1876487 was also associated with
age of onset in the study by Karamohamed et al.21
Analysis of sporadic patients
Seventeen of the 40 genotyped SNPs had MAF ,0.05 and
were excluded from further analysis. In all, 23 SNPs were
used in the final analysis. One highly intercorrelated LD block
of 45 kb (block A) can be defined around the SPR gene
between SNP rs1396107 and rs1161267 (fig 1).
Table 2 Characteristics of the recruited families
Country
Number of
families
Number of siblings
% Male % Female Age at onset (years)*
Affected
genotyped
Unaffected
genotyped
Germany 35 100 44 48.8 51.2 57.4 (10.4)
UK 26 65 24 50.6 49.4 61.2 (7.3)
France 33 84 36 49.4 50.6 56.4 (12.8)
Italy 16 54 12 42.3 57.7 52.8 (16.6)
Netherlands 12 23 22 52.1 47.9 58.2 (11.1)
Total 122 326 138 48.6 51.3 57.6 (11.4)
*Mean (SD).
Table 3 Non-parametric logarithm of odds (LOD) scores of short tandem repeat (STR)
markers with affection status (sibship data)
Marker Distance (cM) Germany UK France Italy Netherlands All
D2S2110 89.76 1.73 2.17* 0.91 1.14 20.41 2.76*
D2S1394 90.29 1.29 0.97 1.41 0.41 0.20 2.08*
D2S2111 90.29 0.95 0.97 1.04 20.25 0.17 1.43
D2S145 90.82 0.99 0.08 1.56 0.41 21.15 1.21
D2S2109 90.82 20.46 20.18 1.78 0.82 0.38 1.12
*p values ,0.05.
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All 14 SNPs within block A were significantly associated
(p,0.05) with Parkinson’s disease, as shown in table 4.
After testing different allelic and genotypic risk effect
models, we show only the recessive risk effect model, which
best fitted to the observed genotype data. The associated
SNPs comprised variants with risk allele frequencies of either
,7% and ,27% in the control population, and were highly
intercorrelated, with r2 values of 0.81 to 0.92. The 11 SNPs
with MAF of 7% seem to be more strongly associated than the
more common SNPs, which include the SNP rs1876487
identified by Karamohamed et al. The estimated relative risks
ranged from 1.21 to 1.57. In a stepwise regression procedure
which tested the allelic association of all significant SNPs
conditioned on alleles at the other significant loci, we were
unable to find an independent signal. It appears that all
significant SNPs within block A (fig 1) potentially referred to
a single causal variant.
A haplotype within block A with a population frequency of
7.6% was also significantly associated with Parkinson’s
disease (p = 0.010), as shown in table 5.
Interestingly, this haplotype is differentiated by 11 muta-
tional steps compared with the next related common
haplotype (frequency 17.5%) in the same block. This ‘‘Yin–
Yang’’ pattern of haplotype relations may indicate recent
positive or balancing selection operating on the block A
variants.28
We further evaluated the three-locus haplotype
(rs2421095–rs1876487–rs1561244) described by
Karamohamed et al,21 which extends between block A and
block B (fig 1). The haplotype AGG, which was most
significantly associated with age of onset in
Karamohamed’s study, was also most significantly associated
in our study (p = 0.002; table 6), albeit with affection status.
We found neither single marker nor haplotype association
with age of onset in our sporadic Parkinson’s disease sample.
DISCUSSION
There is accumulating evidence that the SPR gene is one of
the likely candidates for the PARK3 locus. First, in a large
sample of multiplex families (the GenePD study), one
microsatellite marker D2S1394, which is only 9 kb away
from the SPR gene, showed association with Parkinson’s
disease age at onset.18 The associated allele ‘‘174’’ of this
marker is also common to the segregating core haplotype
observed in two PARK3 families.19 20 Second, a haplotype
harbouring the SPR gene and the promoter SNP rs1876487
was reported to be associated with onset age in the GenePD
study.21 Third, we obtained significant LOD scores with
Parkinson’s disease susceptibility at the two microsatellite
markers D2S2110 and D2S1394, which encompass the SPR
gene, in an independent large sample of multiplex families
(European GSPD study). Interestingly, the English families
with the highest mean age of onset contributed most to this
linkage signal. This result fits well to the finding that the
European genome scan reports a prominent linkage peak at
the SPR region only for late age of onset families.17 We also
found association with age of onset at the markers D2S2110
and rs1876487 in the GSPD family sample. Fourth, we found
association with Parkinson’s disease susceptibility at several
intercorrelated SNP markers and haplotypes in an LD block
spanning the SPR gene in a German sample of patients with
sporadic Parkinson’s disease.
Given all converging evidence, DNA variant(s) in or around
the SPR gene appear to influence Parkinson’s disease onset.
Coding regions of potential PARK3 candidate genes including
SPR have been screened for pathogenic mutations in
Table 4 Genotypic association tests with each allele as the recessive risk allele (sporadic Parkinson’s disease data)
SNP ID
Allele major/
minor Distance Gene position
Frequency of major
allele
Recessive risk model of major
allele
Recessive risk model of minor
allele
Cases Control s p Value
Odds ratio
p Value
Odds ratio
(95% CI) (95% CI)
rs1876488 G/T 72981628 0.809 0.825 0.410 0.73 (0.34 to 1.54) 0.507 1.09 (0.83 to 1.44)
rs1396107 C/T 72988240 0.708 0.751 0.464 0.82 (0.50 to 1.75) 0.024 1.35 (1.03 to 1.75)
rs1508060 T/C 72990328 0.716 0.756 0.486 0.83 (0.49 to 1.40) 0.040 1.31 (1.01 to 1.71)
rs1567230 T/C 72998602 0.897 0.931 0.817 1.21 (0.23 to 6.29) 0.004 1.67 (1.16 to 2.37)
rs2135985 C/A 73001132 0.899 0.928 0.625 1.48 (0.29 to 7.39) 0.012 1.56 (1.09 to 2.20)
rs4852902 G/A 73001656 0.898 0.927 0.624 1.48 (0.29 to 7.41) 0.011 1.56 (1.10 to 2.20)
rs2048170 A/G 73003323 0.900 0.926 0.590 1.53 (0.30 to 7.63) 0.025 1.49 (1.04 to 2.12)
rs1567229 T/C 73018249 SPR promoter 0.900 0.927 0.620 1.49 (0.30 to 7.45) 0.017 1.52 (1.07 to 2.15)
rs1876491 T/G 73018800 SPR promoter 0.906 0.926 0.290 2.97 (0.35 to 24.7) 0.049 1.42 (0.09 to 2.03)
rs2421095 G/A 73025179 SPR promoter 0.899 0.929 0.812 1.22 (0.23 to 6.32) 0.011 1.57 (1.10 to 2.23)
rs1876487 G/T 73026007 SPR promoter 0.677 0.731 0.146 0.71 (0.45 to 1.15) 0.015 1.38 (1.06 to 1.79)
rs6730083 A/G 73027652 SPR intron 2 0.905 0.935 0.787 1.25 (0.24 to 6.49) 0.008 1.16 (1.12 to 2.32)
rs1150500 C/T 73033098 SPR 39UTR 0.901 0.930 0.987 0.98 (0.18 to 5.41) 0.014 1.54 (1.08 to 2.19)
rs1161265 A/G 73033597 SPR 39UTR 0.902 0.929 1.000 1.00 (0.18 to 5.48) 0.025 1.49 (1.04 to 2.12)
rs1161267 G/A 73033836 SPR 39UTR 0.904 0.930 0.970 0.97 (0.17 to 5.36) 0.031 1.47 (1.03 to 2.10)
rs1561244 G/A 73041041 0.789 0.826 0.174 0.58 (0.27 to 1.27) 0.078 1.28 (0.98 to 1.70)
rs1561245 C/T 73042822 0.597 0.636 0.473 0.87 (0.60 to 1.26) 0.060 1.29 (0.98 to 1.70)
rs4852903 G/C 73043640 0.804 0.810 0.909 1.01 (0.77 to 1.34) 0.468 0.78 (0.40 to 1.51)
rs6745468 G/C 73061450 EMX1 intron2 0.801 0.836 0.225 0.59 (0.25 to 1.39) 0.068 1.29 (0.98 to 1.70)
rs999494 G/A 73069050 EMX1 intron2 0.818 0.829 0.491 1.13 (0.83 to 1.46) 0.993 1.00 (0.48 to 2.09)
rs6728203 A/G 73069674 EMX1 0.765 0.800 0.532 0.86 (0.40 to 1.58) 0.061 1.29 (0.98 to 1.68)
rs746212 C/T 7376889 EMX1 0.687 0.705 0.140 0.72 (0.47 to 1.14) 0.840 1.02 (0.78 to 1.33)
rs6722190 C/G 73080248 EMX1 0.672 0.689 0.090 0.69 (0.46 to 1.06) 1.000 1.00 (0.76 to 1.30)
*SNP positions are based on human genome assembly (hg17) and NCBI build 35.
SNP, single nucleotide polymorphism; SPR, sepiapterin reductase gene.
Table 5 Association analysis of common (.1%) block A
haplotypes with affection status; sporadic Parkinson’s
disease data
Haplotype
Case
frequency
Control
frequency p Value
CTTCGATTAGACAG 0.678 0.731 0.012
CTTCGATTATACAG 0.032. 0.027 0.571
TCTCGATTATACAG 0.189 0.165 0.230
TCCAAGCGGTGTGA 0.097 0.065 0.010
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Parkinson’s disease families.20 The failure to detect such
mutations could indicate that the functional variant affects
expression or splicing regulation rather than the protein
structure itself.
A recently published study has revealed a mutation in the
59 UTR of the SPR gene responsible for causing dopa
responsive dystonia.29 SPR is an interesting candidate gene
because it catalyses the conversion of 6-pyrovyl-tetrahydrop-
terin (PTP) to tetrahydrobiopterin (BH4). Previous studies
have shown that BH4 acts not only as a cofactor for TH4 and
is therefore important for dopamine biosynthesis, but also
stimulates NOS isoforms (inducible (iNOS), neural (NOS),
and endothelial (eNOS)).30 It has been suggested that iNOS
confers protection to Parkinson’s disease.
Across studies, there is some variability of the Parkinson’s
disease phenotype mapped to the SPR region. Whereas the
GenePD studies report associations with Parkinson’s disease
onset age,18 the study based on the European GSPD samples
reveals associations with Parkinson’s disease susceptibility.
Of note, however, we could also directly replicate the age of
onset effect at the promoter marker rs1876487 found by
Karamohamed et al.21
It is obvious that affection status and age of onset are
related phenotypes in late onset disorders that show
preclinical and postclinical progression. A factor that influ-
ences the preclinical history of Parkinson’s disease (for
example, the start and rate of the progression of neuronal
loss) will affect the onset age of Parkinson’s disease if a
progression threshold is assumed for the transition from
healthy to disease status. As general mortality (independent
of Parkinson’s disease) increases with age, an age of onset
factor may also be seen as a susceptibility factor, because
early onset factors are upweighted in an association study
dealing with affection status. Different age structures in the
analysed samples may shift the emphasis (detectability)
between the extremes of pure age of onset and pure
susceptibility effects.
In summary, we show that the SPR gene is a likely PARK3
candidate. The association signal appears to be confined to a
haplotype block of 45 kb surrounding the SPR gene. Our data
suggest a single risk variant or age of onset factor of about 7%
frequency with a relative risk of about 1.4 within haplotype
block A. Further evidence of this association signal comes
from the haplotype pattern, which is indicative for recent
natural selection in this genomic region.31
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